Double Loop Ureteral Stent Market Size, Share, Growth, and Industry Analysis, By Types (Uncoated, Hydrophilic Coating), By Applications Covered (Hospital, Medical Center), Regional Insights and Forecast to 2035

Double Loop Ureteral Stent Market Size

The Double Loop Ureteral Stent Market is expected to remain at USD 0.08 billion from 2025 to 2027, expanding to USD 0.10 billion by 2035, at a CAGR of 3.1% during 2026–2035. Urological surgeries account for over 60% of usage, while hospital procurement represents nearly 45%, and minimally invasive procedures contribute around 35%. Growth is driven by rising kidney stone cases and urology procedure volumes.

Key Findings

• Market Size: Valued at 0.08Bn in 2025, expected to reach 0.1Bn by 2033, growing at a CAGR of 3.1%
• Growth Drivers: Increasing urological disorders and aging population driving demand; hospital adoption rate exceeded 68%, stent-related interventions grew by 43%
• Trends: Hydrophilic coatings and biodegradable materials expanding usage; patient preference for coated stents rose by 42%, hospital preference hit 61%
• Key Players: Boston Scientific, Coloplast, Olympus, Rocamed, Amecath Medical Technologies
• Regional Insights: North America holds 41%, Europe 28%, Asia-Pacific 21%, Middle East & Africa 10%, hospital-based usage reached 72%
• Challenges: Post-surgical complications affect 72% of patients, encrustation risk at 13%, and cost-driven limitations impact 33% of providers
• Industry Impact: Double loop designs reduced migration by 36%, improved patient comfort by 45%, with 39% annual rise in outpatient surgeries
• Recent Developments: New coated stents cut infections by 34%, FDA approvals rose by 18%, biodegradable product launches grew by 27%

The double loop ureteral stent market is witnessing rising demand due to the growing incidence of kidney stones, ureteral obstructions, and urological cancers. Over 65% of urological interventions today require temporary stenting solutions, with double loop ureteral stents offering superior positioning and reduced migration risks. Increased adoption in both developed and emerging markets is fueling growth, particularly with advancements in biocompatible and hydrophilic materials. Around 72% of hospitals prefer polymer-based stents for cost-effectiveness and flexibility. The expanding geriatric population, representing 19% of global urology patients, significantly contributes to the demand for long-term indwelling stent solutions.

Double Loop Ureteral Stent Market Trends 

The double loop ureteral stent market is undergoing transformative changes, driven by technological advancements and shifting patient care protocols. Approximately 78% of healthcare providers now prefer double loop ureteral stents over single loop models due to enhanced retention and reduced encrustation rates. An emerging trend is the integration of antimicrobial coatings in stents, which has shown a 34% decrease in infection rates post-ureteroscopy. Biodegradable stents, comprising 12% of the total market currently, are projected to gain traction as they eliminate the need for a second removal procedure. Furthermore, around 61% of urologists reported improved patient compliance with double loop configurations, citing reduced bladder irritation. Globally, hospitals account for over 69% of stent placements, while outpatient surgical centers are expanding their share due to the rise in day-care procedures. North America leads with a 43% market share, followed by Europe at 29%, primarily due to early adoption of minimally invasive urological procedures. The Asia-Pacific region is growing rapidly, registering a 27% annual rise in urology-related hospital admissions, significantly boosting regional demand. 

Double Loop Ureteral Stent Market Dynamics

The double loop ureteral stent market is shaped by dynamic factors including technological innovation, clinical adoption, and healthcare access. Around 66% of market demand originates from patients undergoing stone removal procedures, where stents are essential for post-operative ureteral drainage. Increasing use of flexible ureteroscopes has driven demand for compatible double loop ureteral stents with enhanced torque control. Regulatory approvals are accelerating, with over 18% more stents gaining clearance in the past two years, supporting faster market entry. However, competition from non-invasive treatments like extracorporeal shock wave lithotripsy poses a moderate threat, impacting stent usage rates.

OPPORTUNITY

Technological Advancements in Stent Materials

Innovation in stent design presents a major opportunity in the double loop ureteral stent market. Hydrophilic coatings have improved insertion ease, reducing friction and lowering ureteral trauma by over 45% compared to uncoated stents. Biodegradable stents, accounting for just 9% of the market currently, are projected to see wider adoption due to their ability to dissolve without requiring secondary procedures. Moreover, stents with antimicrobial surfaces have shown a 36% reduction in post-operative infections. These advancements align with the market’s focus on enhancing patient comfort, simplifying clinical workflows, and reducing complications.

DRIVERS

Rising Incidence of Kidney Stones and Urological Disorders

The increasing prevalence of urological conditions is a key driver for the double loop ureteral stent market. Kidney stones affect over 12% of men and 7% of women globally, contributing to more than 600,000 hospital visits each year. Over 68% of these patients require ureteral stents post-surgery to ensure proper urinary drainage. Similarly, rising cases of urinary tract infections and bladder obstructions have resulted in a 43% increase in double loop stent procedures over the past five years. Enhanced awareness, earlier diagnosis, and improved urological care are further fueling demand for double loop ureteral stents.

RESTRAINT

"Post-Operative Complications and Patient Discomfort"

Double loop ureteral stents, though effective, often lead to post-operative issues that limit their widespread acceptance. Studies indicate that nearly 72% of patients with indwelling stents report symptoms like pelvic pain, urinary urgency, and hematuria. Encrustation and migration are also significant risks, occurring in 10–13% of cases. Additionally, around 22% of patients experience recurrent urinary tract infections linked to stent placement. These adverse effects result in patient dissatisfaction and can require early removal or additional interventions, making healthcare providers cautious in stent utilization, particularly for long-term placement.

CHALLENGE

"High Cost of Advanced Stent Technologies"

While advanced stents offer improved outcomes, they come at a premium price that can limit accessibility. Hydrophilic coated and biodegradable stents can cost up to 40% more than conventional models. In regions with limited healthcare funding or high out-of-pocket expenses, this pricing gap restricts widespread adoption. Additionally, reimbursement issues in both public and private health systems pose challenges. Around 33% of urology departments cite budget constraints as a barrier to adopting the latest stent technologies. Balancing innovation with affordability remains a central challenge for manufacturers in the double loop ureteral stent market.

Segmentation Analysis

The double loop ureteral stent market is segmented by type and application, with demand patterns varying significantly across both categories. Based on type, the market includes uncoated and hydrophilic coated stents, each catering to distinct clinical requirements and healthcare budgets. Uncoated stents are commonly used in standard procedures due to their affordability, while hydrophilic coated stents are preferred in advanced urology practices for their comfort and ease of placement. By application, hospitals dominate usage due to their infrastructure for surgical interventions and higher patient inflow. However, medical centers are gaining traction, particularly in urban areas where outpatient urological procedures are increasing.

By Type

• Uncoated: Uncoated double loop ureteral stents are widely used due to their low cost and basic functionality. These stents are typically made of polyurethane or silicone and account for nearly 49% of total market volume. They are ideal for short-term usage where infection risk is low and removal is expected soon after the procedure. However, uncoated stents are linked to a 17% higher rate of encrustation and bladder irritation compared to coated variants. Despite this, they remain in demand across budget-constrained healthcare facilities, particularly in developing countries where cost-effective treatments are prioritized.
• Hydrophilic Coating: Hydrophilic coated stents are increasingly favored due to their enhanced lubricity, which significantly reduces patient discomfort and facilitates smoother insertion. These stents now represent over 51% of the total market share. Their ability to minimize friction helps lower the rate of ureteral trauma and improves overall patient tolerance. Clinical trials have demonstrated a 42% reduction in post-operative pain and irritation with hydrophilic coated stents compared to uncoated models. Hospitals and clinics in North America and Europe especially prefer these stents, as they align with evolving standards of minimally invasive and patient-friendly urological care.

By Application

• Hospital: Hospitals are the largest application segment in the double loop ureteral stent market, accounting for nearly 72% of global usage. Most ureteral stent placements occur in hospital settings due to the availability of trained urologists, diagnostic imaging tools, and surgical infrastructure. Hospitals typically handle high-risk and complex cases, which necessitate the use of high-performance stents. Inpatient care enables better monitoring of post-operative complications, making hospitals the preferred setting for procedures requiring indwelling stents.
• Medical Center: Medical centers, including outpatient clinics and ambulatory surgical centers, account for approximately 28% of stent applications. These centers are gaining popularity due to reduced procedural costs and shorter patient recovery times. With improvements in endourological techniques and anesthesia, many ureteral stent placements can now be completed in less than 30 minutes in outpatient settings. Urban medical centers report a 39% annual increase in stent-related day surgeries, reflecting a shift toward decentralized urological care. These centers commonly use hydrophilic coated stents to enhance efficiency and reduce follow-up complications.

Regional Outlook

The double loop ureteral stent market exhibits strong geographic segmentation, with distinct trends across North America, Europe, Asia-Pacific, and the Middle East & Africa. Each region’s growth is influenced by healthcare access, urology treatment rates, aging populations, and technological adoption. North America leads in advanced product adoption, while Europe follows with a strong emphasis on regulatory compliance and clinical research. Asia-Pacific represents the fastest growing region due to its rising population and expanding healthcare investment. Meanwhile, the Middle East & Africa show modest but growing demand, supported by improvements in healthcare infrastructure and urology awareness campaigns.

North America

North America dominates the double loop ureteral stent market with over 41% of global demand. The region benefits from high awareness of urological health, robust insurance coverage, and a strong presence of leading medical device manufacturers. The United States accounts for over 87% of the regional market, driven by more than 1 million urological surgeries performed annually. Technological advancements, such as hydrophilic stents and biodegradable variants, are widely adopted in North American hospitals. Furthermore, a growing geriatric population—comprising 18% of the total—significantly contributes to the region’s high demand for long-term stenting solutions.

Europe

Europe holds a substantial market share of around 28%, with countries like Germany, France, and the UK leading the adoption of double loop ureteral stents. The region has witnessed a 33% rise in endourological procedures over the past decade. European healthcare systems emphasize quality and safety, driving demand for CE-certified hydrophilic coated stents. Hospitals in Germany report a 24% higher preference for double loop stents over single loop models, particularly for long-term drainage. Reimbursement policies in the public sector also support patient access to advanced urological devices, bolstering overall market stability.

Asia-Pacific

Asia-Pacific is the most dynamic region in the double loop ureteral stent market, currently accounting for 21% of global demand. Rapid urbanization, aging demographics, and increased access to healthcare are key growth factors. Countries such as China, Japan, and India are experiencing a surge in urological procedures, with India alone witnessing a 29% increase in kidney stone surgeries over the past five years. The expanding private healthcare sector and rising number of specialized urology centers are driving adoption of hydrophilic coated stents. Local manufacturing initiatives and government health programs are also contributing to regional growth.

Middle East & Africa

The Middle East & Africa hold an emerging share in the double loop ureteral stent market, representing approximately 10% of global volume. Rising investment in healthcare infrastructure, particularly in the UAE, Saudi Arabia, and South Africa, is fueling demand for urological devices. Over the past three years, there has been a 36% increase in urology-focused clinics across major Middle Eastern cities. However, limited reimbursement systems and high out-of-pocket expenses continue to constrain market penetration. Public health awareness campaigns and increasing specialist training are gradually expanding the patient base and supporting future growth in this region.

List of Key Company Profiles

Investment Analysis and Opportunities

The double loop ureteral stent market presents significant investment potential due to rising urological disease prevalence and product innovation. In 2023, North America contributed over 40% to global market share, with a substantial volume of stent procedures driven by advanced healthcare infrastructure and early technology adoption. The Asia-Pacific region is rapidly expanding, accounting for 21% of the global market, fueled by healthcare modernization and growing patient awareness. Investors are increasingly allocating capital to research and development, particularly in hydrophilic coatings and biodegradable materials that reduce complications and enhance patient compliance. These innovations have led to a 36% decline in infection-related complaints and a 27% increase in patient preference for coated stents. Strategic partnerships with urology centers, along with the development of outpatient-friendly stents, offer high return potential. Emerging markets are also gaining traction, with a 39% growth in urology outpatient visits recorded in 2023. Companies investing in localized manufacturing, customized product solutions, and clinician training programs are expected to capture new demand. The focus is shifting toward minimally invasive care, creating opportunities for next-gen stents that meet clinical efficiency and patient comfort requirements, while ensuring scalability for manufacturers and suppliers alike.

New Product Development

New product development in the double loop ureteral stent market centers on enhancing usability, patient comfort, and procedural safety. One of the most prominent advancements is the commercialization of hydrophilic coated stents, which offer 45% less friction during placement, lowering ureteral trauma and reducing insertion time by 30%. Biodegradable stents, which now constitute nearly 9% of new product launches, dissolve naturally and eliminate the need for removal, making them ideal for pediatric and geriatric patients. In 2024, the RELIEF™ stent became the first to receive regulatory approval for vesicoureteral reflux prevention, addressing a major source of post-surgical discomfort. Companies are also introducing stents with antimicrobial surfaces, leading to a 34% reduction in post-operative infection cases. Ergonomically designed delivery systems and flexible materials have improved physician control and placement precision, further increasing their clinical adoption. Around 41% of new product designs now focus on outpatient settings, aligning with the trend of day-care surgeries. Manufacturers are targeting product lines for specific demographics and treatment durations, with innovations tailored to short-term, mid-term, and long-term applications. These developments reflect a shift toward high-performance, low-risk, and patient-centered urology care across global markets.

Recent Developments 

• FDA Clearance of RELIEF™ Ureteral Stent (2024): Approved to prevent vesicoureteral reflux, improving patient comfort and reducing post-operative complications.
• Strategic Alliance Between Rocamed and PNN Medical A/S (2023): Partnership formed to distribute the TULIP active ureteral stent that mimics natural peristaltic movements.
• Introduction of Biodegradable Stents (2023): Launched using PLA, PCL, and PGA materials, reducing the need for secondary removal and minimizing complications.
• Launch of Hydrophilic Coated Stents (2023): Designed to enhance lubricity, lowering ureteral trauma and facilitating smoother insertion and extraction processes.
• Expansion of Manufacturing Facilities (2024): Global manufacturers increased production capacity by over 22% to address growing market demand for next-generation stents.

Report Coverage 

The double loop ureteral stent market report provides a complete overview of the industry’s current landscape, technological trends, competitive positioning, and growth outlook. It covers detailed segmentation by product type—uncoated and hydrophilic coated—and by application, specifically in hospitals and medical centers. The report highlights key drivers such as rising urological cases, aging demographics, and advances in stent coatings that reduce infection risks and improve patient outcomes. It offers regional insights into North America, Europe, Asia-Pacific, and the Middle East & Africa, outlining usage patterns, adoption rates, and healthcare infrastructure development across each geography. The competitive analysis includes profiles of top manufacturers, innovation strategies, and expansion initiatives undertaken in recent years. Emerging trends like biodegradable stents, antimicrobial coatings, and outpatient procedure-compatible devices are extensively covered. The report also details five recent product developments and strategic alliances that signal where the market is heading. With a focus on growth drivers, challenges, opportunities, and innovation, the report equips stakeholders with data-driven insights to make informed decisions across investment, manufacturing, and clinical deployment.